



Hemophilia and Hemostasis

A Case-Based Approach to Management

2nd edition



Edited by Alice D. Ma, Harold R. Roberts and Miguel A. Escobar

 **WILEY-BLACKWELL**

Contents

Contributors

Foreword

PART 1 Hemophilia A and Hemophilia B

SECTION I General Overview

INTRODUCTION 1 The Hemophilic Ankle: An Update

Pathogenesis of synovitis and cartilage damage
in hemophilia: experimental studies

Radiosynovectomy

Hemophilic arthropathy of the ankle and subtalar
joints

Rehabilitation and physiotherapy

Conclusions

INTRODUCTION 2 The Hemophilic Knee: An Update

Joint aspiration (arthrocentesis)

Conclusions

SECTION II Hemophilia with Inhibitors

CASE STUDY 1 Inhibitor Patient Requiring High Dose Therapy with rVlla as well as Sequential Therapy with FEIBA

CASE STUDY 2 Prophylactic Therapy in a Patient with a High Titer Inhibitor

CASE STUDY 3 Immune Tolerance Induction

CASE STUDY 4 Monitoring During Immune Tolerance Induction

CASE STUDY 5 Factor IX Inhibitors

CASE STUDY 6 Severe Hemophilia B with High Response Inhibitor and Anaphylactic Reaction to Factor IX

CASE STUDY 7 Inhibitor Patient and Dental Surgery

SECTION III Hemophilic Treatment for Procedures

CASE STUDY 8 Deep Vein Thrombosis Prophylaxis in Patients with Hemophilia A Undergoing Orthopedic Surgery

CASE STUDY 9 Prostate Surgery and Hemophilia

CASE STUDY 10 Mild Hemophilia and Intraocular Injections

CASE STUDY 11 Endoscopy/Colonoscopy and Hemophilia

CASE STUDY 12 Dialysis and Hemophilia

CASE STUDY 13 Circumcision

CASE STUDY 14 Pharmacokinetic Studies for Surgery

CASE STUDY 15 Compartment Syndrome

CASE STUDY 16 Successful Eradication of Factor VIII Inhibitor in Patient with Mild Hemophilia A Prior to Hemipelvectomy for Extensive Hemophilic Pseudotumor

CASE STUDY 17 Coronary Artery Disease and Hemophilia

CASE STUDY 18 Valve Replacement and Hemophilia

SECTION IV Treatment for Other Conditions

CASE STUDY 19 Thyroid Biopsy and Hemophilia

CASE STUDY 20 Atrial Fibrillation and Bleeding Disorders

CASE STUDY 21 Chronic Upper Gastrointestinal Bleeding and Hemophilia

CASE STUDY 22 Hematuria

SECTION V Other Issues in Hemophilia Care

CASE STUDY 23 Reproductive Options for Hemophilia A Carriers

CASE STUDY 24 Mild Hemophilia A with
Discrepant FVIII Activity Levels

SECTION VI Compound Diagnoses

CASE STUDY 25 Hemophilia A with
Tuberous Sclerosis and CNS Bleed

CASE STUDY 26 Familial Risk Assessment
for Individuals with Hemophilia A and von
Willebrand Disease

CASE STUDY 27 Hemophilia A and
Hereditary Hemorrhagic Telangiectasia

PART II von Willebrand Disease

SECTION I Management during Procedures

CASE STUDY 28 Type 1 von Willebrand
Disease and Tonsillectomy

CASE STUDY 29 von Willebrand Disease
and Dental Surgery

CASE STUDY 30 von Willebrand Disease and Gastrointestinal Surgery

Gynecologic and Obstetric Considerations: von Willebrand Disease and Obstetric/Gynecologic Procedures

SECTION II Rare Forms of von Willebrand Disease

CASE STUDY 31 Type 2A von Willebrand Disease and Recurrent Gastrointestinal Bleeding

CASE STUDY 32 Type 2B von Willebrand Disease and Thoracic Surgery

CASE STUDY 33 von Willebrand Disease 2N

PART III Other Bleeding Disorders

CASE STUDY 34 Prothrombin Deficiency

CASE STUDY 35 Factor V Deficiency

CASE STUDY 36 Factor VII Deficiency

CASE STUDY 37 Factor X Deficiency

CASE STUDY 38 Factor XI Deficiency

CASE STUDY 39 Factor XIII Deficiency

CASE STUDY 40 Combined Factor V and
Factor VIII Deficiency

CASE STUDY 41 Glanzmann
Thrombaesthesia

CASE STUDY 42 Gardner-Diamond
Syndrome and von Willebrand Disease

CASE STUDY 43 Qualitative Platelet
Disorder

PART IV Acquired Bleeding Disorders

CASE STUDY 44 Acquired FVIII Inhibitor
and B Cell Neoplasm

CASE STUDY 45 FVIII Inhibitor and Lupus
Inhibitor

CASE STUDY 46 Acquired von Willebrand Disease

CASE STUDY 47 A Woman with Bleeding Gums

CASE STUDY 48 Bleeding after Cardiac Surgery

CASE STUDY 49 Bleeding in a Dialysis Patient

CASE STUDY 50 A Woman with Anemia and Hematuria

CASE STUDY 51 Scalp Bleeding in an Older Gentleman

CASE STUDY 52 Hyperfibrinolysis

PART V Thrombotic Disorders

CASE STUDY 53 Heparin-Induced Thrombocytopenia with Thrombosis

CASE STUDY 54 Heparin Skin Necrosis

CASE STUDY 55 Warfarin Skin Necrosis

[CASE STUDY 56 Thoracic Outlet Syndrome](#)

[CASE STUDY 57 Antithrombin Deficiency](#)

[CASE STUDY 58 May-Thurner Syndrome](#)

[CASE STUDY 59 Thrombosis in a Liver
Transplant Patient](#)

[CASE STUDY 60 Combined Thrombophilia](#)

[Index](#)

Hemophilia and Hemostasis

A Case-Based Approach to Management

EDITED BY

Alice D. Ma, MD

Associate Professor of Medicine
Division of Hematology/Oncology
University of North Carolina
Chapel Hill, NC, USA

Harold R. Roberts, MD

Emeritus Professor of Medicine and Pathology
Division of Hematology/Oncology
University of North Carolina
Chapel Hill, NC, USA

Miguel A. Escobar, MD

Associate Professor of Medicine and Pediatrics
Division of Hematology
University of Texas Health Science Center at Houston
Director, Gulf States Hemophilia and Thrombophilia Center
Houston, TX, USA

SECOND EDITION



WILEY-BLACKWELL

A John Wiley & Sons, Ltd., Publication

This edition first published 2013, © 2007, 2013 by John Wiley & Sons Limited.

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

Registered Office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the

understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Hemophilia and hemostasis : a case-based approach to
management / edited by Alice D. Ma,
Harold R. Roberts, Miguel A. Escobar. -- 2nd ed.
p. ; cm.

Rev. ed. of: Haemophilia and haemostasis. c2007.
Includes bibliographical references and index.

ISBN 978-0-470-65976-2 (hardback : alk. paper)

I. Ma, Alice. II. Roberts, H. R. (Harold Ross) III. Escobar,
Miguel A. IV. Haemophilia and haemostasis.

[DNLM: 1. Blood Coagulation Disorders, Inherited--therapy--
Case Reports. 2. Thrombosis--
therapy--Case Reports. WH 322]

616.1'572--dc23

2012017384

A catalogue record for this book is available from the British
Library.

Wiley also publishes its books in a variety of electronic
formats. Some content that appears in print may not be
available in electronic books.

Contributors

Anas Alrwas, MD

Resident, Internal Medicine
University of Texas Health Science Center at Houston
Houston, TX, USA

Tyler Buckner, MD

Hematology Fellow
Pediatric Hematology/Oncology
Adult Hematology
University of North Carolina School of Medicine
Chapel Hill, NC, USA

Benjamin Carcamo, MD

Clinical Assistant Professor
Pediatric Hematology Oncology
Providence Memorial Hospital
Texas Tech University, School of Medicine
El Paso, TX, USA

Miguel A. Escobar, MD

Associate Professor of Medicine and Pediatrics
Division of Hematology
University of Texas Health Science Center at Houston
Director, Gulf States Hemophilia and Thrombophilia Center
Houston, TX, USA

Matthew Foster, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
University of North Carolina School of Medicine
Chapel Hill, NC, USA

Raj Sundar Kasthuri, MD

Assistant Professor of Medicine
Division of Hematology/Oncology
University of North Carolina School of Medicine
Chapel Hill, NC, USA

Kristy Lee, MS, CGC

Clinical Assistant Professor
Department of Genetics
University of North Carolina School of Medicine
Chapel Hill, NC, USA

Alice D. Ma, MD

Associate Professor of Medicine
Division of Hematology/Oncology
University of North Carolina School of Medicine
Chapel Hill, NC, USA

Marshall Mazepa, MD

Senior Fellow
Division of Hematology/Oncology
University of North Carolina School of Medicine
Chapel Hill, NC, USA

Trinh T. Nguyen, DO

Assistant Professor of Pediatrics
Division of Hematology
University of Texas Health Science Center at Houston
Gulf States Hemophilia and Thrombophilia Center
Houston, TX, USA

Nidra Rodriguez, MD

Assistant Professor of Pediatrics
Division of Hematology
The University of Texas Health Science Center at Houston
MD Anderson Cancer Center

Gulf States Hemophilia & Thrombophilia Center
Houston, TX, USA

E. Carlos Rodriguez-Merchan, MD, PhD

Consultant Orthopaedic Surgeon and Associate Professor of
Orthopaedics
La Paz University Hospital
Universidad Autonoma
Madrid, Spain

Jenny M. Splawn, PharmD

Providence Memorial Hospital
El Paso, TX, USA

Tzu-Fei Wang, MD

Fellow
Divisions of Hematology and Oncology
Washington University School of Medicine
Saint Louis, MO, USA

Foreword

I am delighted to respond to the invitation to provide a brief introduction to the second edition of *Hemophilia and Hemostasis: A Case-Based Approach to Management*. The popularity of this text stems from its unique case-based approach. Drs Roberts, Ma, and Escobar are renowned and frequently consulted experts in the management of patients with bleeding disorders. Although the hemophilias and other inherited bleeding disorders have been the focus of a comparatively large body of literature, there are remarkably few randomized-controlled clinical trials on which to base firm evidence-based recommendations. This fact was most recently brought home to me as a member of the team charged with revising the World Federation of Hemophilia's *Treatment Guidelines*; our goal was to provide appropriately graded recommendations of the literature and generally accepted practices for the practicing clinician. Unfortunately, the paucity of high-quality level 1 evidence does not obviate the need to make clinical decisions on a daily basis when caring for patients with bleeding disorders. The authors address these management dilemmas in a comprehensive series of "mini-chapters" that provide an easy reference format for the reader. In this day and age of electronic fingertip access to state-of-the-art reviews on PubMed, it is sometimes said that textbooks are obsolete before they are even published. While there may be some truth to this viewpoint in the case of standard texts, no amount of electronic searching can provide the ready access to the august consensus opinions of these seasoned experts, who have "been down that same road" before. As such, this book is a must for every hematologist or nurse who is charged with taking care of patients with bleeding disorders.

Nigel S. Key MB ChB FRCP
*Harold R. Roberts Distinguished Professor of Medicine
and Pathology and Laboratory Medicine
Chief, Section of Hematology
Director, UNC Hemophilia and Thrombosis Center
Chapel Hill, NC*

PART I

Hemophilia A and Hemophilia B

SECTION I

General Overview

INTRODUCTION 1

The Hemophilic Ankle: An Update

E. Carlos Rodriguez-Merchan

La Paz University Hospital and Universidad Autonoma,
Madrid, Spain

Q What is the latest information regarding the treatment of hemophilic arthropathy in the ankle?

It is well known that the ankles in hemophilic patients tend to bleed, beginning at an early age of 2–5 years. The synovium is only able to reabsorb a small amount of intra-articular blood; if the amount of blood is excessive, the synovium will hypertrophy as a compensating mechanism, so that eventually the affected joint will show an increase in size of the synovium, leading to hypertrophic chronic hemophilic synovitis. The hypertrophic synovium is very richly vascularized, so that small injuries will easily make the joint rebleed. The final result will be the vicious cycle of hemarthrosis-synovitis-hemarthrosis, which eventually will result in hemophilic arthropathy ([Figure I1.1](#)).

Pathogenesis of synovitis and cartilage damage in hemophilia: experimental studies

Hooiveld *et al.* (2004) investigated the effect of a limited number of joint bleedings, combined with loading of the affected joint, in the development of progressive degenerative joint damage. They concluded that experimental joint bleedings, when combined with loading (weight-bearing) of the involved joint, result in features of progressive degenerative joint damage, whereas similar joint hemorrhages without joint loading do not. The authors suggest that this might reflect a possible mechanism of joint damage in hemophilia. In two other papers (Hakobyan *et al.* 2004; Valentino *et al.* 2004), hemophilic arthropathy was studied in animal models. Despite these interesting papers, the pathogenesis of hemophilic arthropathy remains poorly understood.

Figure 11.1 Severe hemophilic arthropathy of the ankle in an adult hemophilia patient.



The best way to protect against hemophilic arthropathy (cartilage damage) is primary prophylaxis beginning at a very early age. Starting prophylaxis gradually with once-weekly injections has the presumed advantage of avoiding the use of a central venous access device, such as a PortaCath, which is otherwise often necessary for frequent injections in very young boys. The decision to institute early full prophylaxis by means of a port has to be balanced against the child's bleeding tendency, the family's social situation, and the experience of the specific hemophilia center. The reported complication rates for infection and thrombosis have varied considerably from center to center. Risk of infection can be reduced by repeated education of patients and staff, effective surveillance routines and limitations on the number of individuals allowed to use the device. In discussing options for early therapy, the risks and benefits should be thoroughly discussed with the parents. For children with inhibitors needing daily infusions for immune tolerance induction, a central venous line is often

unavoidable and is associated with an increased incidence of infections.

From a practical point of view, radiosynovectomy, together with primary prophylaxis to avoid joint bleeding, can help to halt hemophilic synovitis. Ideally, however, radiosynovectomy should be performed before the articular cartilage has eroded. Radiosynovectomy is a relatively simple, virtually painless, and inexpensive treatment for chronic hemophilic synovitis, even in patients with inhibitors, and is the best choice for patients with persistent synovitis.

Figure I1.2 Radiosynovectomy of the ankle with ^{186}Re rhenium.



Radiosynovectomy

Radiosynovectomy is the intra-articular injection of a radioactive material to diminish the degree of synovial hypertrophy and to decrease the number and frequency of hemarthroses ([Figure I1.2](#)). Radioactive substances have been used for the treatment of chronic hemophilic synovitis for many years. Radiation causes fibrosis within the subsynovial connective tissue of the joint capsule and

synovium. It also affects the complex vascular system, in that some vessels become obstructed; however, articular cartilage is not affected by radiation.

The indication for radiosynovectomy is chronic hemophilic synovitis causing recurrent hemarthroses, unresponsive to treatment. There are three basic types of synovectomies: chemical synovectomy, radiosynovectomy, and arthroscopic synovectomy. On average, the efficacy of the procedure ranges from 76 to 80%, and can be performed at any age. The procedure slows the cartilaginous damage which intra-articular blood tends to produce in the long term.

Radiosynovectomy (Yttrium-90, Phosphorus-32, and Rhenium-186) can be repeated up to three times at 6-month intervals. Chemical synovectomy can be repeated weekly up to 10-15 times if rifampicin is used. After 35 years of using radiosynovectomy world wide, no damage has been reported in relation to the radioactive materials. Radiosynovectomy is currently the preferred procedure when radioactive materials are available; however, rifampicin is an effective alternative method if radioactive materials are not available. Several joints can be injected in a single session, but it is best to limit injections to two joints at the same time.

There are two interesting papers that focus on the treatment of chronic hemophilic synovitis. Corrigan *et al.* (2003) have used oral D-penicillamine for the treatment of 16 patients. The drug was given as a single dose in the morning before breakfast. The dose was 5-10 mg/kg bodyweight, not to exceed 10 mg/kg in children, or 750 mg/day in adults. The duration of treatment was 2 months to 1 year (median 3 months). Ten patients had an unequivocal response, 3 had a reduction in palpable synovium and 3 had no response. Minor reversible drug side effects occurred in 2 patients (proteinuria in one and a rash in the other).